Generic Tobi Availability
See also: Generic TOBI Podhaler
TOBI (tobramycin - solution;inhalation)
Has a generic version of Tobi been approved?
A generic version of Tobi has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Tobi and have been approved by the FDA:
Manufacturer: TEVA PHARMS USA
Approval date: October 10, 2013
Strength(s): 300MG/5ML [AN]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tobi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Aminoglycoside formulation for aerosolization
Issued: April 16, 1996
Inventor(s): Smith; Arnold L. & Ramsey; Bonnie W. & Montgomery; Alan B.
Assignee(s): Pathogenesis Corporation
An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a produced by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 .mu., produced by a jet or ultrasonic nebulizer.Patent expiration dates:
- October 19, 2014✓✓
- October 19, 2014
- Tobi solution Consumer Information (Wolters Kluwer)
- Tobi inhalation Consumer Information (Cerner Multum)
- Tobi Advanced Consumer Information (Micromedex®)
- Tobi AHFS DI Monographs (ASHP)
- Tobramycin Consumer Information (Wolters Kluwer)
- Tobramycin powder Consumer Information (Wolters Kluwer)
- Tobramycin solution Consumer Information (Wolters Kluwer)
- Tobramycin Sulfate ADD-Vantage injection Consumer Information (Cerner Multum)
- Tobramycin Sulfate inhalation Consumer Information (Cerner Multum)
- Tobramycin inhalation Consumer Information (Cerner Multum)
- Tobramycin injection Consumer Information (Cerner Multum)
- Tobramycin Inhalation Advanced Consumer Information (Micromedex®)
- Tobramycin Injection Advanced Consumer Information (Micromedex®)
- Tobramycin Sulfate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AN||Solutions and powders for aerosolization. Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded AN. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded BN, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded AN if the bioequivalence standard is based upon in vitro methodology, if bioequivalence needs to be demonstrated by in vivo methodology then the drug products will be coded AB.|